{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:49:40Z","timestamp":1792788580941,"version":"4.5.0"},"reference-count":21,"publisher":"The Company of Biologists","issue":"10","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Research Council of Finland","award":["346656"],"award-info":[{"award-number":["346656"]}],"id":[{"id":"https:\/\/ror.org\/05k73zm37","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Research Council of Finland","award":["338466"],"award-info":[{"award-number":["338466"]}],"id":[{"id":"https:\/\/ror.org\/05k73zm37","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","id":[{"id":"https:\/\/ror.org\/00ckakm23","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","id":[{"id":"https:\/\/ror.org\/03vxy9y38","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Suomen Kulttuurirahasto","id":[{"id":"https:\/\/ror.org\/027xav248","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Turun Yliopisto","id":[{"id":"https:\/\/ror.org\/05vghhr25","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Zebrafish models are widely used to study BRAF-mutant melanoma biology. However, long-term treatment of adult fish with small-molecule BRAF inhibitors remains challenging, and pharmacokinetic data to inform rational dosing strategies are largely lacking for most small molecules in zebrafish. Here, we assessed the pharmacokinetics, metabolism and efficacy of continuously tank-water-administered dabrafenib, a BRAF inhibitor, in adult zebrafish. Dabrafenib was rapidly absorbed from tank water, reaching efficacious plasma levels within 1\u00a0h, but also showed fast elimination kinetics with a half-life of 1.0\u2005h. Most human metabolites of dabrafenib were detected in zebrafish, suggesting conserved metabolic processes. Continuous tank-water administration achieved therapeutically relevant steady-state dabrafenib plasma levels that inhibited BRAF-driven signaling and produced robust efficacy in vivo in a genetic zebrafish model of BRAF-mutant melanoma without apparent toxicity. Together, these results demonstrate that continuous tank-water administration of dabrafenib is a feasible, efficient and well-tolerated dosing strategy in zebrafish melanoma models, and may facilitate dosing of other small-molecule inhibitors, especially those with a short in vivo half-life in zebrafish.<\/jats:p>","DOI":"10.1242\/dmm.052907","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T07:23:12Z","timestamp":1789370592000},"source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetics and efficacy of tank-water-administered dabrafenib, a BRAF inhibitor, in a zebrafish model of melanoma"],"prefix":"10.1242","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4795-8318","authenticated-orcid":false,"given":"Jenna","family":"Villman","sequence":"first","affiliation":[{"name":"Turku Bioscience Centre, University of Turku and \u00c5bo Akademi University 1 , 20520 Turku ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2743-352X","authenticated-orcid":false,"given":"Nikol","family":"Dibus","sequence":"additional","affiliation":[{"name":"Turku Bioscience Centre, University of Turku and \u00c5bo Akademi University 1 , 20520 Turku ,","place":["Finland"]},{"name":"Institute of Biomedicine and Medicity Research Laboratory, University of Turku 2 , 20520 Turku ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4275-8774","authenticated-orcid":false,"given":"Jonas","family":"Huhn","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen 3 , Department of Pharmacy, 81377 Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4724-051X","authenticated-orcid":false,"given":"Anna-Mari","family":"Haapanen-Saaristo","sequence":"additional","affiliation":[{"name":"Turku Bioscience Centre, University of Turku and \u00c5bo Akademi University 1 , 20520 Turku ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-9232-9418","authenticated-orcid":false,"given":"Ilia","family":"Evstafev","sequence":"additional","affiliation":[{"name":"Turku Bioscience Centre, University of Turku and \u00c5bo Akademi University 1 , 20520 Turku ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3178-8449","authenticated-orcid":false,"given":"Alex M.","family":"Dickens","sequence":"additional","affiliation":[{"name":"Turku Bioscience Centre, University of Turku and \u00c5bo Akademi University 1 , 20520 Turku ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1967-9231","authenticated-orcid":false,"given":"Oliver","family":"Scherf-Clavel","sequence":"additional","affiliation":[{"name":"Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen 3 , Department of Pharmacy, 81377 Munich ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5926-2396","authenticated-orcid":false,"given":"Ilkka","family":"Paatero","sequence":"additional","affiliation":[{"name":"Turku Bioscience Centre, University of Turku and \u00c5bo Akademi University 1 , 20520 Turku ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8286-2429","authenticated-orcid":false,"given":"Kari J.","family":"Kurppa","sequence":"additional","affiliation":[{"name":"Turku Bioscience Centre, University of Turku and \u00c5bo Akademi University 1 , 20520 Turku ,","place":["Finland"]},{"name":"Institute of Biomedicine and Medicity Research Laboratory, University of Turku 2 , 20520 Turku ,","place":["Finland"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"237","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"2026101605420643400_DMM052907C1","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1073\/pnas.0406252102","article-title":"tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors","volume":"102","author":"Berghmans","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2026101605420643400_DMM052907C2","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2026101605420643400_DMM052907C3","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMra2034861","article-title":"Recent advances in the treatment of melanoma","volume":"384","author":"Curti","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"2026101605420643400_DMM052907C4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1242\/dmm.024166","article-title":"Long-term drug administration in the adult Zebrafish using oral gavage for cancer preclinical studies","volume":"9","author":"Dang","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"2026101605420643400_DMM052907C5","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s002449900176","article-title":"Toxicity of Binary chemical mixtures: effects on reproduction of zebrafish (Brachydanio rerio)","volume":"32","author":"Ensenbach","year":"1997","journal-title":"Arch. Environ. Contam. Toxicol."},{"key":"2026101605420643400_DMM052907C6","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/S0140-6736(12)60398-5","article-title":"Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial","volume":"379","author":"Falchook","year":"2012","journal-title":"Lancet"},{"key":"2026101605420643400_DMM052907C7","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2026101605420643400_DMM052907C8","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"2026101605420643400_DMM052907C9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00280-013-2324-5","article-title":"A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma","volume":"73","author":"Grippo","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"2026101605420643400_DMM052907C10","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"2026101605420643400_DMM052907C11","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1158\/0008-5472.CAN-14-3319","article-title":"A quantitative system for studying metastasis using transparent zebrafish","volume":"75","author":"Heilmann","year":"2015","journal-title":"Cancer Res."},{"key":"2026101605420643400_DMM052907C12","doi-asserted-by":"publisher","first-page":"e2126","DOI":"10.3791\/2126","article-title":"Intraperitoneal injection into adult zebrafish","volume":"42","author":"Kinkel","year":"2010","journal-title":"J. Vis. Exp."},{"key":"2026101605420643400_DMM052907C13","doi-asserted-by":"publisher","first-page":"3757","DOI":"10.1242\/dev.126.17.3757","article-title":"nacre encodes a zebrafish microphthalmia-related protein that regulates neural-crest-derived pigment cell fate","volume":"126","author":"Lister","year":"1999","journal-title":"Development"},{"key":"2026101605420643400_DMM052907C14","doi-asserted-by":"publisher","first-page":"dmm049401","DOI":"10.1242\/dmm.049401","article-title":"Long-term non-invasive drug treatments in adult zebrafish that lead to melanoma drug resistance","volume":"15","author":"Lu","year":"2022","journal-title":"Dis. Model. Mech."},{"key":"2026101605420643400_DMM052907C15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/zeb.2017.1488","article-title":"ScreenCube: a 3D printed system for rapid and cost-effective chemical screening in adult zebrafish","volume":"15","author":"Monstad-Rios","year":"2018","journal-title":"Zebrafish"},{"key":"2026101605420643400_DMM052907C16","article-title":"Test guideline no. 203; Fish, acute toxicity testing","volume-title":"OECD Guidelines for the Testing of Chemicals","author":"OECD","year":"2025"},{"key":"2026101605420643400_DMM052907C17","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.cub.2005.01.031","article-title":"BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma","volume":"15","author":"Patton","year":"2005","journal-title":"Curr. Biol."},{"key":"2026101605420643400_DMM052907C18","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40262-018-0703-0","article-title":"Clinical pharmacokinetics and pharmacodynamics of Dabrafenib","volume":"58","author":"Puszkiel","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"2026101605420643400_DMM052907C19","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMra041245","article-title":"Management of cutaneous melanoma","volume":"351","author":"Tsao","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"2026101605420643400_DMM052907C20","volume-title":"Tank water-administered dabrafenib in BRAF-mutant zebrafish melanoma model","author":"Villman","year":"2025"},{"key":"2026101605420643400_DMM052907C21","volume-title":"The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio)","author":"Westerfield","year":"2000","edition":"4th edn"}],"container-title":["Disease Models &amp; Mechanisms"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.052907\/3717372\/dmm052907.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.052907\/3721804\/dmm052907.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.biologists.com\/dmm\/article-pdf\/doi\/10.1242\/dmm.052907\/3721804\/dmm052907.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:42:13Z","timestamp":1792143733000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.biologists.com\/dmm\/article\/19\/10\/dmm052907\/373200\/Pharmacokinetics-and-efficacy-of-tank-water"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":21,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1242\/dmm.052907","relation":{},"ISSN":["1754-8403","1754-8411"],"issn-type":[{"value":"1754-8403","type":"print"},{"value":"1754-8411","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"dmm052907"}}